A landmark study from Mass General Brigham Heart and Vascular Institute reveals that patients carrying genetic variants predisposing them to cardiomyopathy benefit significantly from treatment with dapagliflozin, an SGLT2 inhibitor originally developed for type 2 diabetes. The research demonstrates a 32% reduction in heart failure risk among genetically vulnerable populations compared to standard care alone. This finding represents a significant step toward precision medicine in cardiovascular care, where genetic profiling could identify patients most likely to benefit from specific therapies. The study, published in Circulation Research, analyzed data from 12,847 adults and found that patients with pathogenic variants in sarcomere genes experienced the most pronounced protective effects. As genetic testing becomes more accessible, cardiologists may increasingly use these results to personalize treatment strategies and improve outcomes in at-risk populations. Read the full article on GMJ Newsroom.
Was this article helpful?
